184 related articles for article (PubMed ID: 35877722)
41. Synthesis and evaluation of 2'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione derivatives as Mnk inhibitors.
Abdelaziz AM; Basnet SKC; Islam S; Li M; Tadesse S; Albrecht H; Gerber C; Yu M; Wang S
Bioorg Med Chem Lett; 2019 Sep; 29(18):2650-2654. PubMed ID: 31362920
[TBL] [Abstract][Full Text] [Related]
42. The MAP kinase-interacting kinases (MNKs) as targets in oncology.
Xie J; Merrett JE; Jensen KB; Proud CG
Expert Opin Ther Targets; 2019 Mar; 23(3):187-199. PubMed ID: 30650992
[TBL] [Abstract][Full Text] [Related]
43. Using Imidazo[2,1-
Jin X; Qiu T; Xie J; Wei X; Wang X; Yu R; Proud C; Jiang T
ACS Med Chem Lett; 2023 Jan; 14(1):83-91. PubMed ID: 36655132
[TBL] [Abstract][Full Text] [Related]
44. Differential Regulation of ZEB1 and EMT by MAPK-Interacting Protein Kinases (MNK) and eIF4E in Pancreatic Cancer.
Kumar K; Chow CR; Ebine K; Arslan AD; Kwok B; Bentrem DJ; Eckerdt FD; Platanias LC; Munshi HG
Mol Cancer Res; 2016 Feb; 14(2):216-27. PubMed ID: 26609108
[TBL] [Abstract][Full Text] [Related]
45. MNKs act as a regulatory switch for eIF4E1 and eIF4E3 driven mRNA translation in DLBCL.
Landon AL; Muniandy PA; Shetty AC; Lehrmann E; Volpon L; Houng S; Zhang Y; Dai B; Peroutka R; Mazan-Mamczarz K; Steinhardt J; Mahurkar A; Becker KG; Borden KL; Gartenhaus RB
Nat Commun; 2014 Nov; 5():5413. PubMed ID: 25403230
[TBL] [Abstract][Full Text] [Related]
46. The MNK-eIF4E Signaling Axis Contributes to Injury-Induced Nociceptive Plasticity and the Development of Chronic Pain.
Moy JK; Khoutorsky A; Asiedu MN; Black BJ; Kuhn JL; Barragán-Iglesias P; Megat S; Burton MD; Burgos-Vega CC; Melemedjian OK; Boitano S; Vagner J; Gkogkas CG; Pancrazio JJ; Mogil JS; Dussor G; Sonenberg N; Price TJ
J Neurosci; 2017 Aug; 37(31):7481-7499. PubMed ID: 28674170
[TBL] [Abstract][Full Text] [Related]
47. Phosphorylation of the mRNA cap-binding protein eIF4E and cancer.
Yang X; Zhong W; Cao R
Cell Signal; 2020 Sep; 73():109689. PubMed ID: 32535199
[TBL] [Abstract][Full Text] [Related]
48. Design, synthesis and biological evaluation of MNK-PROTACs.
Sun X; Wu Q; Bu H; Pei Y; Guan D; Guo S; Zhou J; Zhang H
Mol Divers; 2024 Mar; ():. PubMed ID: 38498082
[TBL] [Abstract][Full Text] [Related]
49. The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival.
Wheater MJ; Johnson PW; Blaydes JP
Cancer Biol Ther; 2010 Oct; 10(7):728-35. PubMed ID: 20686366
[TBL] [Abstract][Full Text] [Related]
50. The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a eukaryotic initiation factor 4E kinase with high levels of basal activity in mammalian cells.
Scheper GC; Morrice NA; Kleijn M; Proud CG
Mol Cell Biol; 2001 Feb; 21(3):743-54. PubMed ID: 11154262
[TBL] [Abstract][Full Text] [Related]
51. Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells.
Bianchini A; Loiarro M; Bielli P; Busà R; Paronetto MP; Loreni F; Geremia R; Sette C
Carcinogenesis; 2008 Dec; 29(12):2279-88. PubMed ID: 18809972
[TBL] [Abstract][Full Text] [Related]
52. Design, synthesis and biological evaluation of imidazopyridazine derivatives containing isoquinoline group as potent MNK1/2 inhibitors.
Bu H; Yuan X; Wu H; Zhou J; Zhang H
Bioorg Med Chem; 2021 Jun; 40():116186. PubMed ID: 33971490
[TBL] [Abstract][Full Text] [Related]
53. Exosome-mediated miR-7-5p delivery enhances the anticancer effect of Everolimus via blocking MNK/eIF4E axis in non-small cell lung cancer.
Liu S; Wang W; Ning Y; Zheng H; Zhan Y; Wang H; Yang Y; Luo J; Wen Q; Zang H; Peng J; Ma J; Fan S
Cell Death Dis; 2022 Feb; 13(2):129. PubMed ID: 35136028
[TBL] [Abstract][Full Text] [Related]
54. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.
Konicek BW; Stephens JR; McNulty AM; Robichaud N; Peery RB; Dumstorf CA; Dowless MS; Iversen PW; Parsons S; Ellis KE; McCann DJ; Pelletier J; Furic L; Yingling JM; Stancato LF; Sonenberg N; Graff JR
Cancer Res; 2011 Mar; 71(5):1849-57. PubMed ID: 21233335
[TBL] [Abstract][Full Text] [Related]
55. Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2.
Kwiatkowski J; Liu B; Pang S; Ahmad NHB; Wang G; Poulsen A; Yang H; Poh YR; Tee DHY; Ong E; Retna P; Dinie N; Kwek P; Wee JLK; Manoharan V; Low CB; Seah PG; Pendharkar V; Sangthongpitag K; Joy J; Baburajendran N; Jansson AE; Nacro K; Hill J; Keller TH; Hung AW
J Med Chem; 2020 Jan; 63(2):621-637. PubMed ID: 31910010
[TBL] [Abstract][Full Text] [Related]
56. Mnk mediates integrin α6β4-dependent eIF4E phosphorylation and translation of VEGF mRNA.
Korneeva NL; Soung YH; Kim HI; Giordano A; Rhoads RE; Gram H; Chung J
Mol Cancer Res; 2010 Dec; 8(12):1571-8. PubMed ID: 21047768
[TBL] [Abstract][Full Text] [Related]
57. Regulatory effects of a Mnk2-eIF4E feedback loop during mTORC1 targeting of human medulloblastoma cells.
Eckerdt F; Beauchamp E; Bell J; Iqbal A; Su B; Fukunaga R; Lulla RR; Goldman S; Platanias LC
Oncotarget; 2014 Sep; 5(18):8442-51. PubMed ID: 25193863
[TBL] [Abstract][Full Text] [Related]
58. Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells.
Cherian J; Nacro K; Poh ZY; Guo S; Jeyaraj DA; Wong YX; Ho M; Yang HY; Joy JK; Kwek ZP; Liu B; Wee JL; Ong EH; Choong ML; Poulsen A; Lee MA; Pendharkar V; Ding LJ; Manoharan V; Chew YS; Sangthongpitag K; Lim S; Ong ST; Hill J; Keller TH
J Med Chem; 2016 Apr; 59(7):3063-78. PubMed ID: 27011159
[TBL] [Abstract][Full Text] [Related]
59. Discovery of indazole-pyridinone derivatives as a novel class of potent and selective MNK1/2 kinase inhibitors that protecting against endotoxin-induced septic shock.
Dreas A; Kucwaj-Brysz K; Pyziak K; Kulesza U; Wincza E; Fabritius CH; Michalik K; Gabor-Worwa E; Gołas A; Milik M; Masiejczyk M; Majewska E; Pyśniak K; Wójcik-Trechcińska U; Sandowska-Markiewicz Z; Brzózka K; Ostrowski J; Rzymski T; Mikula M
Eur J Med Chem; 2021 Mar; 213():113057. PubMed ID: 33303237
[TBL] [Abstract][Full Text] [Related]
60. Sulfoximine substituted quinazolines for pharmaceutical compositions US 20150005278 (A1): a patent evaluation.
Gopaul K; Koorbanally NA
Expert Opin Ther Pat; 2016 Aug; 26(8):861-9. PubMed ID: 27146589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
